Cancer is too great a challenge to tackle alone. With new partnerships and new technologies spurring rapid innovation, we’re charging ahead to change lives and restore hope for people living with cancer.

“I have never been more excited about the potential of emerging therapeutic agents in oncology. Through the marriage of ground-breaking science, AI, and novel technologies, we aspire to unlock cancer biology that has until now seemed out of reach and bring in a new wave of immunotherapies for areas of high unmet need.”

Valeria Fantin
Head of Oncology Research

NANOBODY® technology

If we string together tiny antibody fragments, could we make medicines that have never been thought of before?

Antibody-Drug Conjugates

What if an antibody could deliver a small amount of medicine straight to tumor cells – could flooding the body with anti-cancer drugs become a thing of the past? 

SYNTHORIN Technology

What if we expand the genetic alphabet – could we access biology in ways that we once thought impossible?

Natural Killer Cell Therapies

What if natural killer cells could be turned into medicines for people with cancer? 

Selective Estrogen Receptor Degraders

What if we could degrade or even destroy the proteins that fuel tumor growth – could we keep some cancers in check?

“Our incredibly talented, creative scientists are motivated to have a meaningful impact on the lives of people with cancer. Leveraging a expansive toolbox that spans small molecules, peptides, proteins, cells, and genes, we’re determined to develop medicines that are smarter, safer, and more effective than ever before.”

Matt Truppo
Global Head of Research Platforms

Our oncology ambition

With new ideas spurring innovation, we’re charging ahead to help change lives and restore hope to people living with cancer

Voices from the Lab

What’s new in immunotherapy?

Nizar El-Murr

A GPS to cancer cells?

Marie-Priscille Brun

One medicine, many targets

Ercole Rao

Explore more

Our Multi-Front Attack on Cancer

Q&A with our Global Head of R&D and Chief Scientific Officer

Oncology R&D at Sanofi

Our teams, technologies, and partnerships

Every step counts

Listening is the real engine behind responsive innovation

Top of this page: An artist’s interpretation of an immune cell attacking a cancer cell. Illustration: Microverse

MAT-GLB-2202118 v 1.0 | June 2022